Neumora Therapeutics Inc (NMRA) News

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation

NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression;...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to...

Neumora Therapeutics to Participate in Upcoming Conferences in May

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities